Stockscreener 앱 받기
178.01
0.66%
-1.19
시간 외 거래:
177.60
-0.41
-0.23%
전일 마감가:
$179.20
열려 있는:
$177.92
하루 거래량:
2.60M
Relative Volume:
0.47
시가총액:
$314.57B
수익:
$55.53B
순이익/손실:
$5.12B
주가수익비율:
48.77
EPS:
3.65
순현금흐름:
$15.62B
1주 성능:
+1.38%
1개월 성능:
-2.77%
6개월 성능:
+5.34%
1년 성능:
+14.93%
1일 변동 폭
$177.29
$179.66
1주일 범위
$174.63
$180.35
52주 변동 폭
$153.58
$207.32
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
178.01 | 314.57B | 55.53B | 5.12B | 15.62B | 2.88 |
|
LLY
Lilly Eli Co
|
783.17 | 704.32B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.37 | 388.07B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
145.05 | 349.23B | 87.70B | 14.68B | 19.03B | 6.05 |
|
MRK
Merck Co Inc
|
99.70 | 252.20B | 63.17B | 12.15B | 14.84B | 4.77 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is AbbVie Stock a Buy? - MSN
Pharma company spends ₹1.91 crore on foreign travel of doctors, gets reprimanded - The Hindu
The Smartest Dividend Stocks to Buy With $1,000 Right Now - The Motley Fool
Looking Into AbbVie's Recent Short Interest - Benzinga
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance Australia
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - Benzinga
AbbVie Sues PTO to Extend Life of Venclexta Cancer Drug Patent - Bloomberg Law
Why AbbVie Inc. (ABBV) Is Among the Best Stocks to Buy and Hold for 3 Years? - Yahoo Finance
Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc - GuruFocus.com
Pharma Dept reprimands AbbVie Healthcare for unethical marketing practices - Business Standard
Pharma dept reprimands AbbVie Healthcare for unethical marketing practices - Business Standard
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Pharma company hauled up for taking doctors on foreign trips - The Times of India
PhRMA dues fell almost $100 million as major drugmakers exited - STAT
AbbVie’s Skyrizi Rockets into Top 5 in Media Monitors Radio Report - Radio Ink
AbbVie call volume above normal and directionally bullish - TipRanks
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs - Insider Monkey
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution - Yahoo Finance
Is AbbVie Inc. (ABBV) the Best Dividend Stock for Steady Income? - Insider Monkey
Abbvie - Contract Pharma
AbbVie (NYSE:ABBV) Stock Price Up 2%Here's What Happened - MarketBeat
AbbVie, Novartis and drug industry win court battle in larger 340B war - Crain's Chicago Business
Alembic Pharma Gains USFDA Approval for Epilepsy Treatment - Devdiscourse
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AI & Data Convergence - AbbVie
AbbVie (NYSE:ABBV) Trading Down 0.5% After Insider Selling - MarketBeat
AbbVie acquiring Madison-based Nimble Therapeutics for $200 million - Milwaukee Journal Sentinel
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline - Kilgore News Herald
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? - Insider Monkey
Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2024-2031: Stryker Corporation, - EIN News
Abbvie SVP Kevin Buckbee sells stock for $310,032 - Investing.com India
Kevin K. Buckbee Sells 1,800 Shares of AbbVie Inc. (NYSE:ABBV) Stock - MarketBeat
ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL - Citeline News & Insights
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - Bloomberg Law
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - Investing.com
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
AbbVie's (ABBV) Overweight Rating Reiterated at Piper Sandler Companies - MarketBeat
Bain Sued Over Cerevel Trades Before $8.7 Billion Sale to AbbVie - Bloomberg Law
AbbVie (NYSE:ABBV) Price Target Raised to $220.00 at Piper Sandler - MarketBeat
4 Big Drug Stocks That May Continue to Outperform in 2025 - Yahoo Finance
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? - Yahoo! Voices
Spinal Cord Injury Therapeutics Market Set to Witness Significant Growth by 2024-2031: AbbVie Inc, Pfizer - EIN News
Immunology Market Huge Growth in Future Scope 2024-2031 | AbbVie - openPR
Is AbbVie Ready for a Bullish Turn? - Investing.com
Botulinum Toxin in Urology Market Top PlayersAbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC. - openPR
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
0.23%
자본화:
|
볼륨(24시간):